159 related articles for article (PubMed ID: 1494808)
41. Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
Wahab NA; Zainudin S; AbAziz A; Mustafa N; Sukor N; Kamaruddin NA
Arch Iran Med; 2016 Sep; 19(9):671-3. PubMed ID: 27631184
[TBL] [Abstract][Full Text] [Related]
42. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
43. Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
Cremaschi V; Abate A; Cosentini D; Grisanti S; Rossini E; Laganà M; Tamburello M; Turla A; Sigala S; Berruti A
Expert Opin Pharmacother; 2022 Aug; 23(12):1413-1424. PubMed ID: 35876101
[TBL] [Abstract][Full Text] [Related]
44. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
45. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer.
Scarpellini M; Tononi A; Pasquini E; Oliverio G; Fattori PP; Gianni L; Desiderio F; Nicolini M; Ravaioli A
J Chemother; 1994 Jun; 6(3):211-5. PubMed ID: 7983505
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
[TBL] [Abstract][Full Text] [Related]
47. 5-Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma.
Schlumberger M; Ostronoff M; Bellaiche M; Rougier P; Droz JP; Parmentier C
Cancer; 1988 Apr; 61(8):1492-4. PubMed ID: 3349416
[TBL] [Abstract][Full Text] [Related]
48. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
49. ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
Yarom N; Stewart D; Avruch L; Malik R; Wells J; Jonker DJ
Anticancer Res; 2011 Nov; 31(11):3921-5. PubMed ID: 22110220
[TBL] [Abstract][Full Text] [Related]
50. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
51. [Diagnosis and treatment for adrenocortical carcinoma].
Iihara M; Obara T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):342-5. PubMed ID: 15045937
[TBL] [Abstract][Full Text] [Related]
52. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
[TBL] [Abstract][Full Text] [Related]
53. Adrenocortical carcinoma. Our experience.
Favia G; Lumachi F; Carraro P; D'Amico DF
Minerva Endocrinol; 1995 Mar; 20(1):95-9. PubMed ID: 7651289
[TBL] [Abstract][Full Text] [Related]
54. [A case of adrenal cortical carcinoma].
Oida T; Souma T; Doi H; Hida S; Takasu K
Hinyokika Kiyo; 2002 Nov; 48(11):667-70. PubMed ID: 12512139
[TBL] [Abstract][Full Text] [Related]
55. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
[TBL] [Abstract][Full Text] [Related]
56. Advanced gastric cancer with multiple lymph node metastasis successfully treated with etoposide, adriamycin and cisplatin.
Shigemitsu K; Naomoto Y; Matsuno T; Gochi A; Isozaki H; Tanaka N
J Gastroenterol Hepatol; 2001 May; 16(5):581-5. PubMed ID: 11350560
[TBL] [Abstract][Full Text] [Related]
57. Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
Chalasani S; Vats HS; Banerjee TK; McKenzie AK
Clin Med Res; 2009 Jun; 7(1-2):48-51. PubMed ID: 19574489
[TBL] [Abstract][Full Text] [Related]
58. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Bajetta E; Di Bartolomeo M; de Braud F; Bozzetti F; Bochicchio AM; Comella P; Fagnani D; Farina G; Ferroni C; Franchi R
Eur J Cancer; 1994; 30A(5):596-600. PubMed ID: 8080673
[TBL] [Abstract][Full Text] [Related]
59. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
60. Long-term survival in recurrent adrenocortical cancer.
Shuayb M; Das A; Uddin MN
BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
